112 related articles for article (PubMed ID: 23507590)
1. [Cancer treatment response evaluation based on imaging modalities, such as computed tomography, magnetic resonance imaging and FDG-PET].
Endo M; Aramaki T; Moriguchi M; Sawada A; Asakura K; Bekku E
Gan To Kagaku Ryoho; 2013 Mar; 40(3):294-8. PubMed ID: 23507590
[TBL] [Abstract][Full Text] [Related]
2. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy.
Desar IM; van Herpen CM; van Laarhoven HW; Barentsz JO; Oyen WJ; van der Graaf WT
Cancer Treat Rev; 2009 Jun; 35(4):309-21. PubMed ID: 19136215
[TBL] [Abstract][Full Text] [Related]
3. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
4. (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go.
Herrmann K; Benz MR; Krause BJ; Pomykala KL; Buck AK; Czernin J
Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):620-32. PubMed ID: 22231582
[TBL] [Abstract][Full Text] [Related]
5. Assessing tumor response to therapy.
Weber WA
J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
Qu X; Huang X; Yan W; Wu L; Dai K
Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
[TBL] [Abstract][Full Text] [Related]
7. [Correlation of FDG-PET and MRI/CT with histopathology in primary diagnosis, lymph node staging and diagnosis of recurrency of head and neck cancer].
Pöpperl G; Lang S; Dagdelen O; Jäger L; Tiling R; Hahn K; Tatsch K
Rofo; 2002 Jun; 174(6):714-20. PubMed ID: 12063600
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
[TBL] [Abstract][Full Text] [Related]
9. [18F]FDG-PET-CT for early monitoring of tumor response: when and why.
Storto G; Nicolai E; Salvatore M
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):167-80. PubMed ID: 19293765
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
11. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP; Kramer H; Reiser MF; Glaser C
Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
[TBL] [Abstract][Full Text] [Related]
12. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
13. PET and PET/CT in pediatric oncology.
Jadvar H; Connolly LP; Fahey FH; Shulkin BL
Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
[TBL] [Abstract][Full Text] [Related]
14. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
15. Impact of FDG-PET/CT in the management of lymphoma.
Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H
Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging of malignant lymphoma.
Vermoolen MA; Kersten MJ; Fijnheer R; van Leeuwen MS; Kwee TC; Nievelstein RA
Expert Rev Hematol; 2011 Apr; 4(2):161-71. PubMed ID: 21495926
[TBL] [Abstract][Full Text] [Related]
17. Monitoring cancer treatment with PET/CT: does it make a difference?
Weber WA; Figlin R
J Nucl Med; 2007 Jan; 48 Suppl 1():36S-44S. PubMed ID: 17204719
[TBL] [Abstract][Full Text] [Related]
18. Tumor biology-guided radiotherapy treatment planning: gross tumor volume versus functional tumor volume.
Guha C; Alfieri A; Blaufox MD; Kalnicki S
Semin Nucl Med; 2008 Mar; 38(2):105-13. PubMed ID: 18243845
[TBL] [Abstract][Full Text] [Related]
19. Radiological evaluation of the therapeutic response of malignant diseases: status quo, innovative developments and requirements for radiology.
Höink AJ; Heindel W; Buerke B
Rofo; 2014 Oct; 186(10):927-36. PubMed ID: 25122173
[TBL] [Abstract][Full Text] [Related]
20. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community.
Liu Y; Litière S; de Vries EG; Sargent D; Shankar L; Bogaerts J; Seymour L
Eur J Cancer; 2014 Jan; 50(2):260-6. PubMed ID: 24239447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
